113 related articles for article (PubMed ID: 32441463)
1. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
Matsuki T; Okamoto I; Fushimi C; Sawabe M; Kawakita D; Sato H; Tsukahara K; Kondo T; Okada T; Tada Y; Miura K; Omura G; Yamashita T
Cancer Med; 2020 Jul; 9(14):5015-5024. PubMed ID: 32441463
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
[TBL] [Abstract][Full Text] [Related]
3. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706
[TBL] [Abstract][Full Text] [Related]
4. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
[TBL] [Abstract][Full Text] [Related]
5. The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.
Nishiyama N; Hirobe M; Kikushima T; Matsuki M; Takahashi A; Yanase M; Ichimatsu K; Egawa M; Hayashi N; Negishi T; Masumori N; Kitamura H
BMC Urol; 2020 Jul; 20(1):110. PubMed ID: 32711491
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
[TBL] [Abstract][Full Text] [Related]
7. Sixth-Week Immune-Nutritional-Inflammatory Biomarkers: Can They Predict Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
Olgun P; Diker O
Curr Oncol; 2023 Dec; 30(12):10539-10549. PubMed ID: 38132403
[TBL] [Abstract][Full Text] [Related]
8. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab.
Kim N; Yu JI; Park HC; Yoo GS; Choi C; Hong JY; Lim HY; Lee J; Choi MS; Lee JE; Kim K
Cancer Immunol Immunother; 2021 Jun; 70(6):1593-1603. PubMed ID: 33231725
[TBL] [Abstract][Full Text] [Related]
9. Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
Suzuki S; Taguchi Y; Kitabayashi T; Sato N; Kaya H; Abe T; Endo T; Suzuki H; Kawasaki Y; Yamada T
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38730986
[No Abstract] [Full Text] [Related]
10. Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis.
Fu W; Wang K; Yan S; Wang X; Tang B; Chang J; Wang R; Wu T
Dose Response; 2020; 18(3):1559325820942065. PubMed ID: 32821253
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis.
Xie Y; Li H; Hu Y
Medicine (Baltimore); 2023 Nov; 102(45):e35962. PubMed ID: 37960803
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada.
Zereshkian A; Shafi R; Pond GR; Hotte SJ
J Immunother; 2024 May; 47(4):123-127. PubMed ID: 38230590
[TBL] [Abstract][Full Text] [Related]
13. Validation and comparison of prognostic scoring systems in patients with head and neck squamous cell carcinoma treated with nivolumab.
Takenaka Y; Takemoto N; Otsuka T; Nishio M; Tanida M; Fujii T; Hayashi K; Suzuki M; Mori M; Yamamoto Y; Uno A; Inohara H
Jpn J Clin Oncol; 2024 Mar; ():. PubMed ID: 38555496
[TBL] [Abstract][Full Text] [Related]
14. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma.
Ueta R; Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Ouchi K; Kasahara Y; Taniguchi S; Yoshida Y; Sasaki K; Shirota H; Takahashi M; Ishioka C
Oncology; 2024; 102(3):252-259. PubMed ID: 37708868
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
Ikoma T; Shimokawa M; Matsumoto T; Boku S; Yasuda T; Shibata N; Kurioka Y; Takatani M; Nobuhisa T; Namikawa T; Kitagawa H; Hanazaki K; Doi K; Shimada T; Tsumura T; Marusawa H; Kanaya S; Morita S; Inokuma T; Nagai H; Yasui H; Satake H
Cancer Immunol Immunother; 2023 Feb; 72(2):427-435. PubMed ID: 35927359
[TBL] [Abstract][Full Text] [Related]
16. Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab.
Haas M; Lein A; Fuereder T; Schnoell J; Brkic FF; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Oct; 41(5):727-736. PubMed ID: 37603206
[TBL] [Abstract][Full Text] [Related]
17. The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab.
Lee RH; Truong A; Wu X; Kang H; Algazi AP; El-Sayed IH; George JR; Heaton CM; Ryan WR; Ha PK; Wai KC
Head Neck; 2024 Jan; 46(1):129-137. PubMed ID: 37897202
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort.
Makino T; Nakai S; Momose K; Yamashita K; Tanaka K; Miyata H; Yamamoto S; Motoori M; Kimura Y; Ushimaru Y; Hirao M; Matsuyama J; Akamaru Y; Kurokawa Y; Eguchi H; Doki Y
Esophagus; 2024 May; ():. PubMed ID: 38717686
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors.
Sakai A; Ebisumoto K; Iijima H; Yamauchi M; Teramura T; Yamazaki A; Watanabe T; Inagi T; Maki D; Okami K
Discov Oncol; 2023 Aug; 14(1):158. PubMed ID: 37642856
[TBL] [Abstract][Full Text] [Related]
20. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A; Guven DC; Koksal B; Karaoglan BB; Kivrak D; Ismayilov R; Aslan F; Sutcuoglu O; Yazici O; Kadioglu A; Alan O; Majidova N; Erciyestepe M; Ozcan E; Akdag G; Taban H; Kaya AO; Guliyev M; Yildirim N; Sakalar T; Yazilitas D; Unal C; On S; Biter S; Demirci NS; Senler FC; Kemal Y; Halil OD; Gullu I; Aksoy S
Eur Arch Otorhinolaryngol; 2024 May; ():. PubMed ID: 38795147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
